Gene therapy in epilepsy.

Epilepsia
Véronique RibanMatthew J During

Abstract

Results from animal models suggest gene therapy is a promising new approach for the treatment of epilepsy. Several candidate genes such as neuropeptide Y and galanin have been demonstrated in preclinical studies to have a positive effect on seizure activity. For a successful gene therapy-based treatment, efficient delivery of a transgene to target neurons is also essential. To this end, advances have been made in the areas of cell transplantation and in the development of recombinant viral vectors for gene delivery. Recombinant adeno-associated viral (rAAV) vectors in particular show promise for gene therapy of neurological disorders due to their neuronal tropism, lack of toxicity, and stable persistence in neurons, which results in robust, long-term expression of the transgene. rAAV vectors have been recently used in phase I clinical trials of Parkinson's disease with an excellent safety profile. Prior to commencement of phase I trials for gene therapy of epilepsy, further preclinical studies are ongoing including evaluation of the therapeutic benefit in chronic models of epileptogenesis, as well as assessment of safety in toxicological studies.

References

Sep 1, 1985·Epilepsia·M DragunowR Laverty
Nov 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·T R FlotteB J Carter
Feb 1, 1996·Neuron·J L Noebels
Sep 1, 1997·Nature Medicine·O Isacson, X O Breakefield
Nov 5, 1997·Nature Biotechnology·R ZuffereyD Trono
Oct 6, 1997·Journal of Neurophysiology·G J Klapstein, W F Colmers
Oct 20, 1998·Annals of Neurology·M A YenariG K Steinberg
Mar 24, 1999·Trends in Neurosciences·A VezzaniW F Colmers
Jul 13, 1999·Journal of Neurophysiology·P R PatryloA Williamson
Nov 1, 2000·Proceedings of the National Academy of Sciences of the United States of America·J McLaughlinR Sapolsky
Jun 19, 2001·Proceedings of the National Academy of Sciences of the United States of America·A HuberD Boison
Sep 5, 2001·Current Opinion in Genetics & Development·J Rathjen, P D Rathjen
Nov 8, 2001·Proceedings of the National Academy of Sciences of the United States of America·M KokaiaT Hökfelt
Apr 19, 2002·The New England Journal of Medicine·Salima Hacein-Bey-AbinaMarina Cavazzana-Calvo
May 16, 2002·Proceedings of the National Academy of Sciences of the United States of America·Külliki SaarUlo Langel
Oct 16, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·Rebecca HabermanThomas McCown
Nov 5, 2002·Methods : a Companion to Methods in Enzymology·Marc J RuitenbergJoost Verhaagen
Dec 5, 2002·International Journal of Hematology·Salima Hacein-Bey-AbinaMarina Cavazzana-Calvo
Sep 2, 2003·Journal of Neuroscience Research·Johan JakobssonCecilia Lundberg
Nov 19, 2003·The European Journal of Neuroscience·En-Ju D LinMatthew J During
Jan 23, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Nicolette GouderDetlev Boison
Mar 27, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Cristina RichichiAnnamaria Vezzani

❮ Previous
Next ❯

Citations

Apr 1, 2009·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·F Edward Dudek
Feb 1, 2011·Epilepsia·Panos TheofilasDetlev Boison
Apr 28, 2009·Epilepsy Currents·Graeme J Sills
May 4, 2010·Annals of Indian Academy of Neurology·H V Srinivas
Apr 4, 2009·Epilepsy & Behavior : E&B·Margaret P JacobsJohn W Swann
Feb 15, 2015·Nanomedicine : Nanotechnology, Biology, and Medicine·Cristina Soto-SánchezEduardo Fernández
Oct 2, 2012·Experimental Neurology·M Decressac, R A Barker
Jun 23, 2016·Journal of Neurochemistry·Katarzyna LepetaConstanze Seidenbecher
Jan 16, 2020·Epilepsy Currents·Devin K BinderUNKNOWN AES/NINDS Epilepsy Benchmarks Stewards
Mar 11, 2020·Expert Review of Neurotherapeutics·Antonella RivaPasquale Striano
Mar 15, 2019·Acta neurologica Belgica·Amir MehdizadehSina Raeisi
Oct 6, 2020·Frontiers in Pharmacology·Luis Felipe Santos MenezesElisabeth Ferroni Schwartz
Mar 11, 2010·Current Opinion in Neurology

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.